Articles
Systematic literature review of evidence in amyloid light-chain amyloidosis
- Journal/Conference:
- J Comp Eff Res
- Author(s):
- Lee, C.; Lam, A.; Kangappaden, T.; Olver, P.; Kane, S.; Tran, D.; Ammann, E.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Blood, Oncology
- Condition:
- AL amyloidosis
Overall Survival Associated with Image-guided Thermal Ablation (IGTA) and Stereotactic Body Radiation Therapy (SBRT) for patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Regression Analysis
- Journal/Conference:
- American Thoracic Society (ATS) international conference 2022
- Author(s):
- Laeseke P, Ng C, Ferko, N, Naghi, A, Wright G, Zhang Y, Kalsekar I, Laxmanan B, Ghosh S, Zhou M, Szapary P, Pritchett M
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Lung
- Condition:
- Lung Cancer
Outcomes of Image-guided Thermal Ablation (IGTA) and Stereotactic Body Radiation Therapy (SBRT) for Patients with Pulmonary Metastases: A Systematic Review and Meta-Analysis
- Journal/Conference:
- American College of Chest Physicians 2022
- Author(s):
- Naghi A, Laeseke P, Ng C, Ferko N, Hall A, Wright GWJ, Zhang Y, Kalsekar I, Laxmanan B, Ghosh SK, Zhou M, Szapary P, Pritchett M
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Lung
- Condition:
- Lung Cancer
Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective
- Journal/Conference:
- Interventional Neuroradiology
- Author(s):
- Sudhakar R. Satti , Emilie Kottenmeier, Alia Khaled, George W.J. Wright and Heather L. Cameron
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Brain
- Condition:
- Brain Arteriovenous Malformations
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
- Journal/Conference:
- Americal Journal of Cardiovascular Drugs
- Author(s):
- Rozenbaum, M.H.; Tran, D.; Bhambri, R.; Nativi-Nicolau, J.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Cardiovascular
- Condition:
- ATTR-CM
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
- Journal/Conference:
- Journal of Medical Economics
- Author(s):
- Kilcoyne, A.; Jordan, E.; Zhou, A.; Thomas, K.; Pepper, A.N.; Chappell, D; Amarapala, M.; Hughes, A.; Thompson, M.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Respiratory
- Condition:
- COVID-19
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England
- Journal/Conference:
- Clinicoeconomic Outcomes Research
- Author(s):
- Kilcoyne, A.; Jordan, E.; Thomas, K.; Pepper, A.N.; Zhou, A.; Chappell, D.; Amarapala, M.; Thériault, R.K.; Thompson, M.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Respiratory
- Condition:
- COVID-19
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis
- Journal/Conference:
- Multiple Sclerosis and Related Disorders
- Author(s):
- Samjoo IA, Klotz L, Giovannoni G, Drudge C, Haltner A, Worthington E, Zhao M, Brennan R, Häring DA, Cameron C, Adlard N
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
A systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis
- Journal/Conference:
- Clinical and Experimental Neuroimmunology
- Author(s):
- Drudge C, Zhao M, Tanaka S, Tanaka N, Otaka H, Kawachi I, Häring DA, Brennan R, Adlard N, Samjoo IA
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
- Journal/Conference:
- BMC Health Services Research
- Author(s):
- Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, Drea E, Vogelzang NJ
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Oncology
- Condition:
- Prostate Cancer